Stryker

Worldwide Headquarters
2825 Airview Boulevard
Kalamazoo
Michigan
49002
United States

Tel: 269-385-2600
Fax: 269-385-1062

2020 Ideal Employer
Show jobs for this employer

232 articles with Stryker

  • Stryker announced that it has priced an offering of $600 million aggregate principal amount of its 0.600% Notes due 2023.

  • Stryker (NYSE:SYK) will participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020. Preston Wells, Vice President, Investor Relations and Spencer Stiles, Group President, Orthopaedics and Spine, will represent the Company in a presentation scheduled for 8:00 a.m. Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.

  • Acquisition adds two new and rapidly growing segments to surgical portfolio

  • Stryker (NYSE: SYK) announced today that it has completed the previously announced acquisition of Wright Medical Group N.V. (NASDAQ: WMGI), a global medical device company focused on extremities and biologics. “This acquisition enhances our global market position in trauma and extremities, providing significant opportunities to advance innovation and reach more patients,” said Kevin Lobo, Chairman and Chief Executive Officer, Stryker. “We

  • Stryker (NYSE: SYK) announced today that it intends to complete the acquisition of Wright Medical Group N.V. (NASDAQ: WMGI) by effectuating the mergers described in the tender offer statement on Schedule TO filed by Stryker B.V., an indirect, wholly owned subsidiary of Stryker, with the U.S. Securities and Exchange Commission on December 13, 2019, as amended. 

  • Stryker announced that Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol Myers Squibb, has been elected to its Board of Directors, effective December 1, 2020.

  • Stryker (NYSE: SYK) announced today that all required regulatory approvals have been obtained for the previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI) by Stryker B.V., an indirect, wholly owned subsidiary of Stryker. The tender offer is being made pursuant to the purchase agreement, dated November 4, 2019, among Stryker, Stryker B.V. and Wright Medical. “We are pleased

  • The response to the COVID-19 pandemic has included unprecedented measures to slow the spread of the virus taken by local governments and health care authorities globally, including the postponement of deferrable medical procedures and social contact restrictions, which have had a significant negative impact on our operations and financial results.

  • ProCuity Bed Series designed to enhance patient and caregiver safety for all acuity levels, reduce in-hospital falls

  • Stryker announced today the expansion of its lateral spine portfolio with the full launch of the Niagara Lateral Access System following the completion of 600 surgeries. With the addition of Niagara, Stryker offers a comprehensive and integrated portfolio of minimally invasive lateral solutions for treating spinal deformities

  • Stryker announced that it has surpassed one million Mesa Pedicle Screw implantations globally since its launch in 2006.

  • Stryker (NYSE:SYK) announced that it will host a conference call on Thursday, October 29, 2020 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended September 30, 2020 and provide an operational update. Final operating results for the quarter ended September 30, 2020 will be released at 4:05 p.m. that day. To participate in the conference call dial (877) 702-4565 (domestic) or (647) 689-5532 (intern

  • Stryker’s AxSOS 3 ® Ankle Fusion System Offers Innovative Plates That Are Designed to Fit a Range of Patients New System Includes Titanium Plates with Streamlined Instrumentation and Updated Screw Offerings MAHWAH, N.J.--( BUSINESS WIRE )-- Stryker’s Trauma & Extremities division today announced the launch of its AxSOS 3 Ankle Fusion System, an ankle fusion titanium plate system intended for the fusion of the tibio-talar joint. This press rele

  •  Stryker announced today that it has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation.   Aneurysms in the posterior circulation rupture more

  • Stryker (NYSE:SYK) reported operating results for the second quarter of 2020: The response to the COVID-19 pandemic has included unprecedented measures to slow the spread of the virus taken by local governments and health care authorities globally, including the postponement of deferrable medical procedures and social contact restrictions, which have had a significant negative impact on Stryker’s operations and financial results. Secon

  • Stryker announced that its Board of Directors has declared a quarterly dividend of $0.575 per share payable October 30, 2020 to shareholders of record at the close of business on September 30, 2020, representing an increase of approximately 11% versus the prior year and unchanged from the previous quarter.

  • Stryker announced that Stryker B.V., an indirect, wholly owned subsidiary of Stryker, has extended the offering period of its previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V.

  • Stryker (NYSE:SYK) announced that it will host a conference call on Thursday, July 30, 2020 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended June 30, 2020 and provide an operational update. Final operating results for the quarter ended June 30, 2020 will be released at 4:05 p.m. that day. To participate in the conference call dial (877) 702-4565 (domestic) or (647) 689-5532 (international) and

  • Stryker announced that it has priced the following senior notes: $650 million aggregate principal amount of the Company’s 1.150% Notes due 2025, $1 billion aggregate principal amount of the Company’s 1.950% Notes due 2030, and $650 million aggregate principal amount of the Company’s 2.900% Notes due 2050.

  • Stryker announced that its Board of Directors has declared a quarterly dividend of $0.575 per share payable on July 31, 2020 to shareholders of record at the close of business on June 30, 2020, representing an increase of approximately 11% versus the prior year and unchanged from the previous quarter.